Patents Examined by Kathleen Kahler Fonda
-
Patent number: 5624679Abstract: The present invention relates to a purified, easily produced poly-.beta.-1.fwdarw.4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-GlcNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are attached in a .beta.-1.fwdarw.4 conformation, and which is free of proteins, and substantially free of single amino acids, and other organic and inorganic contaminants. In addition, derivatives and reformulations of p-GlcNAc are described. The present invention further relates to methods for the purification of the p-GlcNAc of the invention from microalgae, preferably diatom, starting sources. Still further, the invention relates to methods for the derivatization and reformulation of the p-GlcNAc. Additionally, the present invention relates to the uses of pure p-GlcNAc, its derivatives, and/or its reformulations.Type: GrantFiled: June 6, 1995Date of Patent: April 29, 1997Assignee: Marine Polymer Technologies, Inc.Inventors: John N. Vournakis, Sergio Finkielsztein, Ernest R. Pariser, Mike Helton
-
Patent number: 5622834Abstract: The present invention relates to a purified, easily produced poly-.beta.-1.fwdarw.4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-GlcNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are attached in a .beta.-1.fwdarw.4 conformation, and which is free of proteins, and substantially free of single amino acids, and other organic and inorganic contaminants. In addition, derivatives and reformulations of p-GlcNAc are described. The present invention further relates to methods for the purification of the p-GlcNAc of the invention from microalgae, preferably diatom, starting sources. Still further, the invention relates to methods for the derivatization and reformulation of the p-GlcNAc. Additionally, the present invention relates to the uses of pure p-GlcNAc, its derivatives, and/or its reformulations.Type: GrantFiled: December 1, 1993Date of Patent: April 22, 1997Assignee: Marine Polymer Technologies, Inc.Inventors: John N. Vournakis, Sergio Finkielsztein, Ernest R. Pariser, Mike Helton
-
Patent number: 5623064Abstract: The present invention relates to a purified, easily produced poly-.beta.-1.fwdarw.4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-GlcNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are attached in a .beta.-1.fwdarw.4 conformation, and which is free of proteins, and substantially free of single amino acids, and other organic and inorganic contaminants. In addition, derivatives and reformulations of p-GlcNAc are described. The present invention further relates to methods for the purification of the p-GlcNAc of the invention from microalgae, preferably diatom, starting sources. Still further, the invention relates to methods for the derivatization and reformulation of the p-GlcNAc. Additionally, the present invention relates to the uses of pure p-GlcNAc, its derivatives, and/or its reformulations.Type: GrantFiled: December 1, 1994Date of Patent: April 22, 1997Assignee: Marine Polymer Technologies, Inc.Inventors: John N. Vournakis, Sergio Finkielsztein, Ernest R. Pariser, Mike Helton
-
Patent number: 5622937Abstract: This invention relates to compounds that inhibit the binding of E-selectin or P-selectin to sialyl-Lewis.sup.x or sialyl-Lewis.sup.a presented on a cell surface having the general structure: ##STR1## This invention also relates to methods of inhibiting the binding of E-selectin or P-selectin to sialyl-Lewis.sup.x or sialyl-Lewis.sup.a presented on a cell surface using said compounds and to pharmaceutically active compositions comprising compounds that inhibit the binding of E-selectin to sialyl-Lewis.sup.x and to methods of treatment of septic shock, ARDS, Crohn's disease, chronic inflammatory diseases, such as psoriasis and rheumatoid arthritis, and reperfusion injuries that occurs following heart attacks, strokes and organ transplants and to the treatment of cancer.Type: GrantFiled: May 1, 1996Date of Patent: April 22, 1997Assignee: Texas Biotechnology CorporationInventors: Timothy P. Kogan, Brian Dupre, Huong Dao, Pamela J. Beck
-
Patent number: 5622936Abstract: The invention relates to a method for the preparation of glycoconjugates of phosphorus amides with the general formula ##STR1## where the connection of the sugar with the phosphoric acid amide mustard residue, and the ifosfamide mustard residue, respectively, occurs preferably in the 1-position, and where R.sub.1 and R.sub.2 ; which can be the same or different, denote hydrogen, lower C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.6 haloalkyl and where as sugar there can be present mono-, di-, or polysaccharides in all existing isomeric and enantiomeric forms, wherein in a known way protected brominated sugars are conjugated with the respective phosphorus compounds, and freed of the protective residues, and to the use of said compounds as anti-tumour drugs.Type: GrantFiled: June 19, 1990Date of Patent: April 22, 1997Assignee: Deutsches Krebsforschungszentrum Stiftung des offentlichen RechtsInventors: Manfred Wiessler, Michael Dickes
-
Patent number: 5620858Abstract: Diagnostic and therapeutic compositions which comprise the .alpha.Gal(1-4).beta.Gal subunit are described. These compositions permit the rapid diagnosis and treatment of enteric infections caused by E. coli that produce shiga-like toxins (SLT).Type: GrantFiled: September 27, 1993Date of Patent: April 15, 1997Assignee: Synsorb Biotech Inc.Inventors: Glen D. Armstrong, Robert M. Ratcliffe
-
Patent number: 5621086Abstract: The present invention is drawn to methods of manufacturing a sialic acid derivative suitable for industrial production. With a method of the present invention, Tetra-O-acetylsialic acid (4a) and acetylcytidine-5'-O-amidite (5a) are condensed in the presence of an acid catalyst to obtain a phosphite (6a). The phosphite (6a) is oxidized with t-butylhydroperoxide to obtain a phosphate (9a). The phosphate (9a) is deprotected with an alkali to obtain CMP-sialic acid (1a). ##STR1## The present invention further encompasses a novel sialic acid derivative.Type: GrantFiled: August 31, 1995Date of Patent: April 15, 1997Assignee: Japan Tobacco Inc.Inventors: Yasuhiro Kajihara, Takashi Ebata, Hisashi Kodama
-
Patent number: 5614615Abstract: Sialyl Lewis X mimetics incorporating fucopeptides are synthesized and shown to mimic the configuration and essential functional groups of sialyl Lewis X in space. The fucopeptides exhibit substantially the same biological activity as sialyl Lewis X in the E-selectin binding assay and can be employed for blocking neutrophil inflammatory conditions.Type: GrantFiled: August 25, 1995Date of Patent: March 25, 1997Assignee: The Scripps Research InstituteInventor: Chi-Huey Wong
-
Patent number: 5612321Abstract: Grafted polysaccharide compositions comprising polysaccharides grafted with antioxidants on at least one hydroxyl group of the polysaccharide. The use of antioxidant grafted polysaccharides or antioxidant grafted crosslinked polysaccharides as a treatment for arthritis, as a drug delivery vehicle, to reduce the incidence of post-operative adhesion formation, to promote the healing of chronic wounds and ulcers, and as a component of cosmetic formulations.Type: GrantFiled: June 22, 1995Date of Patent: March 18, 1997Assignee: Hercules IncorporatedInventor: Tuyen T. Nguyen
-
Patent number: 5605892Abstract: An aqueous agent comprising at least one arginine amide selected from the group consisting of (2R,4R)-4-methyl-1-[N.sup.2 -((RS)-3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl]-2-piper idinecarboxylic acid, monohydrate thereof and pharmacologically acceptable salts thereof, and at least one compound selected from the group consisting of cyclodextrin and caffeine; a method for improving the solubility of arginine amide in water, comprising adding at least one compound selected from the group consisting of cyclodextrin and caffeine; and a method for stabilizing arginine amide in water, comprising adding caffeine. According to the present invention, the solubility of arginine amide in water can be enhanced to, for example, a concentration permitting inhibition of fibrin formation at the time of entoptic operation. In addition, the stability of arginine amide in water can be enhanced with less irritation of the eye.Type: GrantFiled: April 5, 1996Date of Patent: February 25, 1997Assignees: Senju Pharmaceutical Co., Ltd., Mitsubishi Chemical CorporationInventors: Yoshifumi Ikejiri, Shirou Sawa
-
Patent number: 5605893Abstract: A therapeutic food composition for treatment of diabetic patients to diminish fluctuations in blood sugar levels and prevent hypoglycemic episodes, comprising per unit about 20-50 grams of nutrients including a slowly absorbed or digested complex carbohydrate, preferably cornstarch; a more rapidly absorbed complex carbohydrate; protein; and fat, but substantially no simple sugars. Diabetic patients may be treated to diminish blood sugar fluctuations and prevent hypoglycemia via the administration of the novel food composition as an evening or pre-bedtime snack or during the daytime hours to patients receiving insulin therapy or engaging in activities that might provoke hypoglycemia.Type: GrantFiled: April 7, 1995Date of Patent: February 25, 1997Assignee: Children's Hospital of Los AngelesInventor: Francine Kaufman
-
Patent number: 5604207Abstract: The inventive compounds are analogues of sialyl Le.sup.x that inhibit cellular adhesion between a selectin and cells that express sialyl Le.sup.x on their surfaces, and their synthetic intermediates. An inventive compound has structure A, ##STR1## wherein Z is hydrogen, C.sub.1 -C.sub.6 acyl or ##STR2## Y is C(O), SO.sub.2, HNC(O), OC(O) or SC(O); R.sup.1 is an aryl, a substituted aryl or a phenyl C.sub.1 -C.sub.3 alkylene group, wherein an aryl group has one five- or six-membered aromatic ring, a fused five/six-membered aromatic ring, or two fused six-membered aromatic rings, which rings are hydrocarbyl, monooxahydrocarbyl, monothiahydrocarbyl, monoazahydrocarbyl or diazahydrocarbyl rings, and a substituted aryl group is an aryl group having a halo, trifluoromethyl, nitro, C.sub.1 -C.sub.18 alkyl, C.sub.1 -C.sub.18 alkoxy, amino, mono-C.sub.1 -C.sub.18 alkylamino, di-C.sub.1 -C.sub.18 alkylamino, benzylamino, C.sub.1 -C.sub.18 alkylbenzylamino, C.sub.1 -C.sub.18 thioalkyl or C.sub.1 -C.sub.Type: GrantFiled: November 28, 1994Date of Patent: February 18, 1997Assignee: Cytel CorporationInventors: Shawn A. DeFrees, Federico C. A. Gaeta, John J. Gaudino, Zhongli Zheng, Masaji Hayashi
-
Patent number: 5601799Abstract: The present invention relates to a D 25 polysaccharide compound whose lipid has been partially removed and to its derivatives, wherein at least 85% by weight, preferably 90% of the compound, exists in aqueous solution in monomeric form. The 30 kD molecular weight polysaccharide compound extracted from the membrane proteoglycan of the bacterium Klebsiella pneumoniae is mentioned in particular. The amount of palmitic fatty acids which is bound to it in esterified form does not exceed 0.01% by weight of the compound and the amount of palmitic fatty acids which is associated with it in the free form does not exceed 0.1% by weight of the compound.Type: GrantFiled: January 6, 1995Date of Patent: February 11, 1997Assignee: Pierre Fabre MedicamentInventors: Hans Binz, Lucien Dussourd D'Hinterland, Gerard Normier, Alain Le Pape, Michel Favaron, Souhail Delassan
-
Patent number: 5599801Abstract: Heparin fractions obtained by nitrous depolymerization, containing at most 150 ppb of total N-nitroso compounds, prepared by subjecting heparins of natural origin which have been depolymerized with a nitrite to the action of UV radiation.Type: GrantFiled: May 6, 1994Date of Patent: February 4, 1997Assignee: Choay S.A.Inventors: Jean-Fran.cedilla.ois Branellec, Jos e Espejo, Philippe Picart
-
Patent number: 5599915Abstract: Sialyl Lewis.sup.x mimetic compounds are disclosed that are free of sialyl groups and glycosidically-linked fucosyl groups. These compounds exhibit about the same inhibition of selectin-medicated cellular adhesion as does sialyl Lewis.sup.x itself.Type: GrantFiled: March 21, 1995Date of Patent: February 4, 1997Assignee: The Scripps Research InstituteInventors: Chi-Huey Wong, Tetsuya Kajimoto
-
Patent number: 5593969Abstract: A compound of the formula: ##STR1## wherein: each of R.sub.1, R.sub.1 ', R.sub.2 and R.sub.2 ' independent of each other is a substituted or unsubstituted, branched or linear C.sub.1-12 alkyl, alkene or alkyne group, R.sub.3 is OH, OCH.sub.3, CH.sub.2 COOH or ##STR2## wherein each of R.sub.2" and R.sub.2 '41 independent of each other is a substituted or unsubstituted, branched or linear C.sub.1-12 alkyl, alkene or alkyne group and:A=NH.sub.2, X=P(OH), Y=Z=C, B=OCH.sub.3, orA=OH, X=P(OH), X=Z=C, B (if present)=OCH.sub.3, orA=OCO(CH.sub.2).sub.n NH.sub.2, X=P(OH), Y=Z=C, B=OCH.sub.3,wherein n=1-10, orA=OH, X=P(OH), Y=Z=C, B=O(CH.sub.2).sub.n CO.sub.2 H, wherein n=1-10, orA=OH, X=P(OH), Y=Z=C, B=(CH.sub.2).sub.n CO.sub.2 H, wherein n=1-10, orA=NH.sub.2, X=Z=C, Y=P(OH), B=OCH.sub.3, orA=OH, X=Z=C, Y=P(OH), B (if present)=OCH.sub.3, orA=OCO(CH.sub.2).sub.n NH.sub.2, X=Z=C, Y=P(OH), B=OCH.sub.3, wherein n=1-10, orA=OH, X=Z=C, Y=P(OH), B=O(CH.sub.2).sub.n CO.sub.2 H, wherein n=1-10, orA=OH, X=Z=C, Y=P(OH), B=(CH.Type: GrantFiled: September 17, 1993Date of Patent: January 14, 1997Assignee: IGEN IncorporatedInventors: Balreddy Kamireddy, Michael J. Darsley, David M. Simpson, Richard J. Massey
-
Patent number: 5589465Abstract: Novel glycolipid derivatives of Formula (I): ##STR1## wherein R is a long chain alkyl, or their salts are disclosed. These compounds act as a ligand for selectin family and exhibit a remarkable inhibitory effect on the binding of selectin family to its native ligand sialyl Lewis.sup.x.Type: GrantFiled: March 1, 1995Date of Patent: December 31, 1996Assignees: Akira Hasegawa, Kanebo Ltd.Inventors: Hideharu Ishida, Makoto Kiso, Akira Hasegawa
-
Patent number: 5589588Abstract: A sulfated acid amide having heparin-like properties of the formula:(R.sub.1)--NH--R--NH--(R.sub.1)whereR.sub.1 is a di-, tri- or tetra-saccharide acid selected from cellobiose, cellotriose, cellotetrose, maltose, maltotriose and maltotetrose or mixtures thereof, andR is an alkylene of from 3 to 12 carbons, and is optionally substituted with one or more hydroxyls.Type: GrantFiled: March 30, 1993Date of Patent: December 31, 1996Assignee: Reliable Biopharmaceutical CorporationInventor: Joseph A. Toce
-
Patent number: 5583208Abstract: A ganglioside GM3 derivative containing fluorine atoms in a ceramide portion thereof, represented by the formula: ##STR1## in which m is an integer of at least 2, n is an integer of 0 to 7 provided that m is larger than n, and R represents an alkyl group or a fluoroalkyl group is disclosed.Type: GrantFiled: May 8, 1995Date of Patent: December 10, 1996Assignee: Daikin Industries, Ltd.Inventors: Takao Iida, Yutaka Ohira
-
Patent number: 5583213Abstract: The present specification is directed to a novel process to prepare an activated sulfated polysaccharide which may then be used in subsequent reactions or processes to bind the reactive polysaccharide with a nucleophilic agent or an aminated surface. The activating process comprises the steps of initially forming a polysaccharide tetraalkylammonium salt by contacting an aqueous mixture of a sulfated polysaccharide salt with a cation exchange resin to give a polysaccharide free acid and then contacting the polysaccharide free acid with a tetraalkylammonium hydroxide to give the polysaccharide tetraalkylammonium salt, and subsequently forming an activated sulfated polysaccharide by contacting the polysaccharide tetraalkylammonium salt of step i) with a coupling reagent in an aprotic organic solvent at ambient temperatures for a period of time sufficient to form the activated sulfated polysaccharide.Type: GrantFiled: May 12, 1995Date of Patent: December 10, 1996Assignee: Minnesota Mining and Manufacturing CompanyInventors: Masao Yafuso, Robert J. Linhardt